Orgenesis Inc. (NASDAQ:ORGS – Get Free Report) shares traded up 490% on Monday . The company traded as high as $0.59 and last traded at $0.59. 100 shares were traded during trading, a decline of 90% from the average daily volume of 959 shares. The stock had previously closed at $0.10.
Orgenesis Stock Down 94.4%
The stock has a market cap of $169,026.30, a P/E ratio of -0.00 and a beta of 3.22. The company’s 50 day moving average price is $0.31 and its two-hundred day moving average price is $0.39.
Orgenesis Company Profile
Orgenesis, Inc is a cell and gene therapy company that develops and commercializes point-of-care manufacturing platforms for autologous and allogeneic therapies. The company offers an end-to-end solution that spans from R&D through clinical and commercial production, targeting applications in oncology, neurology, and various rare diseases. Orgenesis’ technology platforms are designed to streamline the complex processes involved in cell isolation, genetic modification, expansion and cryopreservation.
The company’s flagship offering is its automated Prodigy® platform, which integrates cell processing workflows into a closed, single-use system.
See Also
- Five stocks we like better than Orgenesis
- Photronics Is Quietly Becoming a Key Winner From the AI Boom
- Looking Beyond NVIDIA? These 3 AI ETFs Are Beating the Market
- Palantir’s Kool-Aid Moment: The Math Behind Karp’s Forecast
- OpenAI’s Jalapeño Chip Could Change the AI Hardware Race
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.
